Ticker AIMT – Aimmune Therapeutics Inc – sales, description, marketcap – Tickerday.com

AIMT

Aimmune Therapeutics Inc

–

Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;

Marketcap: 2.25B; Volume: 242.06K; AvgVol 3m: 2.10M; Beta: 1.74;

Cost estimate:

P/E: –; EPS: -4.49; EPS growth quarter/prev quarter: -5.30%;

EPS growth this year: -8.20%; EPS growth past 5 years: ;

EPS ttm: -4.49;

P/S: 3764.40; P/B: 12.47; P/Cashflow: 7.19; P/FCF: ;

Sales: 570.00K; Sales growth quarter/prev quarter: ; Sales growth past 5 years: ;

Profitability:

Gross Margin: ; Profit Margin: ; Operating Margin: ;

ROA – return on assets: -92.70%; ROE – return on equity: -170.90%; LT Debt/Equity: 0.73; Total Debt/Equity: 0.73;

Dividend: –; Dividend Yield (%): –;

Insider Ownership: 0.90%; Insider Transactions:258.33%;

Institutional Ownership: 87.10%; Institutional Transactions: 2.96%;

Data update: 07.10.2020.